Rarecells
is headquartered in New York, New York. Patrizia Paterlini Brechot is the Founder of Rarecells. Rarecells has raised a total of $5M in funding. Rarecells has 3 followers on Owler. Rarecells has an estimated revenue of <$1M and an estimate of less <10 employees.Rarecells
is headquartered in New York, New York. Patrizia Paterlini Brechot is the Founder of Rarecells. Rarecells has raised a total of $5M in funding. Rarecells has 3 followers on Owler. Rarecells has an estimated revenue of <$1M and an estimate of less <10 employees.
News
May 14, 2026
FinanzNachrichten
Rarecells: Rarecells, Inc.: Rarecells Recognized Among Top 5 Disruptive Health Technologies with the Potential to Change the World by Maynooth University's Innovation Value Institute
Sep 09, 2025
FinanzNachrichten
Rarecells: Rarecells, Inc.: Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor Heterogeneity Detection by Synergistic Combination of ctDNA and ISET CTC-DNA in Patients with Early-Stage Lung Cancer
Jun 18, 2025
Benzinga
Rarecells: Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board
Jul 20, 2023
PR Newswire
Press Release: Rarecells : Rarecells, Inc. announces a breakthrough publication on Circulating Giant Cancer Cells detected in patients with MDS
Sep 06, 2022
Markets Insider
Rarecells: Rarecells, Inc. announces Appointment of New Director to the Board
Apr 06, 2021
Cision Canada
Press Release: Rarecells : ISET technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS
Oct 28, 2020
FinanzNachrichten
Rarecells: ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells
May 07, 2019
FinanzNachrichten
Rarecells: RARECELLS DIAGNOSTICS Announces That Its Founder and Scientific Advisor, Professor Patrizia Paterlini-Bréchot, Is Named European Inventor Award 2019 Finalist
Dec 08, 2016
Blackbird
Press Release: Rarecells : Circulating Tumor Cell Market Trends, Consumption, Drivers, Strategies, Applications and Competitive Landscape 2027
Nov 03, 2014
BUSINESS WIRE
Press Release: Rarecells : Ground-breaking Study confirms that the ISET by Rarecells® test allows early diagnosis of Lung Cancer in At-Risk Population through the Sensitive and Reliable detection of Circulating Tumor Cells